Papillary thyroid microcarcinoma should not be used as the basis for postoperative 131I therapy
Journal Title: Journal of Surgery : Concepts & Practice - Year 2023, Vol 28, Issue 6
Abstract
[Objective] To analyze the clinicopathological data of patients with papillary thyroid microcarcinoma (PTMC) and papillary thyroid non-microcarcinoma (non-PTMC) who received 131I therapy retrospectively, and compare the therapeutic response of the two groups of patients, so as to guide 131I therapy decisions for PTMC patients. [Methods] A total of 1 118 patients with papillary thyroid carcinoma (PTC) underwent 131I therapy in the Department of Nuclear Medicine, Tianjin Medical University General Hospital from January 2015 to December 2020 were enrolled. Chi-square test and Mann-Whitney U test were used to compare the differences of clinicopathological features and 131I therapy， therapeutic response between two groups. The incomplete response （IR）rate curves of the two groups were plotted by Kaplan-Meier analysis.[Results] The proportion of patients with multifocal, involvement of bilateral thyroid lobes in PTMC group were higher than those in non-PTMC group, and the proportion of patients with extra-thyroid extension, T4, N1b, stimulated thyroglobulin(sTg)>10 μg/L, and high risk stratified were lower than those in non-PTMC group (P<0.05). Most patients in PTMC group received remnant ablation for the first time, while more patients in non-PTMC group received adjuvant therapy and therapy for known disease (P<0.05). There was no statistically significant difference in 131I therapeutic response, the rates of excellent response(ER) and IR in two groups, and the differences in curves of IR rate between the two groups were also no statistically significance (P>0.05). [Conclusions] PTMC has a certain degree of invasiveness. As long as the patients were comprehensively evaluated and the standard 131I therapy was adopted, the treatment outcomes of patients with PTMC and non-PTMC were roughly the same. Therefore, the clinical value of the definition of PTMC is extremely limited in the formulation of 131I therapeutic dose regimens.
Authors and Affiliations
Xiaoyu CAI, Ruiguo ZHANG, Yujing HU, Renfei WANG, Yanzhu BIAN
Keywords
Related Articles
- EP ID EP750926
- DOI 10.16139/j.1007-9610.2023.06.08
- Views 26
- Downloads 1
Emerging developments in immune checkpoint inhibitor therapy for gastroenteropancreatic neuroendocrine neoplasm
Immunotherapies targeting immune checkpoints have undergone rapid evolution, and have been preliminary explored in treatment of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in recent years. However, their pot...
Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia
[Objective] To investigate the effect of sugammadex for reversal of neuromuscular blockade postoperatively in the patients with CT guided radiofrequency ablation of hepatic carcinoma under general anesthesia. [Methods] T...
Comparative efficacy of precut over a pancreatic duct stent and transpancreatic precut sphincterotomy for difficult biliary cannulation in ERCP
[Objective] To compare the efficacy of precut over a pancreatic duct stent (PPDS) and transpancreatic precut sphincterotomy (TPS) for difficult biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP)...
Application of pylorus-preserving gastrectomy in surgical treatment for early gastric cancer and interpretation of guidelines and consensus
Endoscopic resection (ER) and laparoscopic surgery are the main methods for treatment of early gastric cancer (EGC). Radical gastrectomy(RG) and lymph node dissection are required for the patients who don’t meet the indi...
Endoscopic treatment of gallbladder diseases
In recent years, with the rapid development of digestive endoscopy technology, new endoscopic diagnosis and treatment techniques and methods for gallbladder diseases have emerged, showing unique advantages, vitality and...